Artivion Stock Forecast for 2023 - 2025 - 2030
Updated on 03/27/2024
Artivion Stock Forecast and Price Target
In recent months, notable analysts have provided yearlong price targets for Artivion, with the average target coming in at $25.00. If it were to be achieved, this would result in a potential upside of approximately 24.88 percent from the most recent closing price in March, 2024. The high end is $28.00, and the low is $22.00. You may be interested in rivals even if you aren't interested in Artivion stock.
24.88% Upside
Artivion Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Artivion's Price has seen a drop from $34.39 to $0.00 – a 100.00% decrease. In the next year, analysts expect Fair Value to reach $0.00 – an increase of 100.00%. For the next eight years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
MDT Stock Forecast | Medtronic | Outperform |
11
|
$85.50 | Buy/Sell | $92.47 | 11.11% |
BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$66.12 | Buy/Sell | $70.14 | 8.89% |
BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$239.50 | Buy/Sell | $284.47 | 16.91% |
Artivion Revenue Forecast for 2023 - 2025 - 2030
Artivion's Revenue has increased by 39.79% In the last three years, going from $253.23M to $354.00M. In the next year, analysts expect Revenue to reach $384.26M – an increase of 8.55%. For the next eight years, the forecast is for Revenue to grow by 14.10%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$90.83 | Buy/Sell | $91.18 | 1.84% |
4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$43.48 | Buy/Sell | $44.86 | 3.50% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SWAV Stock Forecast | Shockwave Medical | Outperform |
4
|
$257.74 | Buy/Sell | $239.91 | 4.76% |
PEN Stock Forecast | Penumbra | Outperform |
9
|
$241.62 | Buy/Sell | $258.62 | 19.40% |
GETI B Stock Forecast | Getinge AB | Outperform |
18
|
kr206.40 | Buy/Sell | kr226.10 | 9.01% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MMSI Stock Forecast | Merit Medical Systems | Outperform |
14
|
$74.61 | Buy/Sell | $89.25 | 19.29% |
IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$36.22 | Buy/Sell | $46.60 | 20.10% |
688016 Stock Forecast | Shanghai MicroPort Endovascula... | Buy |
18
|
¥186.35 | Buy/Sell | ¥238.98 | 26.64% |
Artivion EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Artivion's EBITDA has decreased from $27.68M to $14.57M – a 47.36% drop. Next year, analysts are expecting EBITDA to reach $73.54M – an increase of 404.74%. Over the next seven years, the forecast is for EBITDA to grow by 543.94%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ATRC Stock Forecast | AtriCure | Outperform |
8
|
$36.92 | Buy/Sell | $55.00 | 55.74% |
LMAT Stock Forecast | LeMaitre Vascular | Outperform |
18
|
$64.78 | Buy/Sell | $59.86 | 8.06% |
1302 Stock Forecast | LifeTech Scientific | Buy |
16
|
HK$1.87 | Buy/Sell | HK$2.97 | 58.82% |
Artivion EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Artivion's EBIT has decreased by 222.27%, going from $6.96M to $-8.51M. 4 analysts predict Artivion's EBIT will decrease by 375.68% in the next year, reaching $23.46M. By 2030, professionals predict that Artivion's EBIT will decrease by 627.78%, to $44.91M.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SILK Stock Forecast | Silk Road Medical, Inc | Outperform |
7
|
$16.00 | Buy/Sell | $12.33 | 18.75% |
ANGO Stock Forecast | AngioDynamics | Outperform |
8
|
$5.47 | Buy/Sell | $16.33 | 155.94% |
AVR Stock Forecast | Anteris Technologies Ltd | Buy |
10
|
$19.20 | Buy/Sell | $28.00 | 45.83% |
Artivion EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Artivion's EPS has seen a drop from $0.25 to $0.00 – a 100.00% decrease. In the next year, analysts expect EPS to reach $-0.03 – an increase of 100.00%. For the next eight years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ELUT Stock Forecast | Elutia | Buy |
2
|
$3.94 | Buy/Sell | $0.00 | 26.90% |
RUA Stock Forecast | RUA Life Sciences |
0
|
£0.10 | Buy/Sell | £0.66 | 560.00% | |
AVGR Stock Forecast | Avinger | Outperform |
9
|
$3.31 | Buy/Sell | $5.00 | 51.06% |